ReviewBMC biochemistry2007
The Fanconi anemia pathway and ubiquitin.
Review in BMC biochemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.British journal of cancer · 2023Article
- [Progeroid syndromes : Aging, skin aging, and mechanisms of progeroid syndromes].Dermatologie (Heidelberg, Germany) · 2023Review
- Comparative transcriptomic analysis of gonadal development and renewal in the ovoviviparous black rockfish (Sebastes schlegelii).BMC genomics · 2021Article
- Detection and analysis of common pathogenic germline mutations in Peutz-Jeghers syndrome.World journal of gastroenterology · 2021Article
- Article
- Roundup causes embryonic development failure and alters metabolic pathways and gut microbiota functionality in non-target species.Microbiome · 2020Article
- Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer.BMC systems biology · 2018Article
- Article
- Induction of centrosome amplification by formaldehyde, but not hydroquinone, in human lymphoblastoid TK6 cells.Environmental and molecular mutagenesis · 2015Article
- Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.Oncotarget · 2015Article
- Functional characterization of breast cancer using pathway profiles.BMC medical genomics · 2014Article
- PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells.Translational oncology · 2014Article
- Application of toxicogenomic profiling to evaluate effects of benzene and formaldehyde: from yeast to human.Annals of the New York Academy of Sciences · 2014Review
- Heterogeneity in the entire genome for three genotypes of peach [Prunus persica (L.) Batsch] as distinguished from sequence analysis of genomic variants.BMC genomics · 2013Article
- Turnover of BRCA1 involves in radiation-induced apoptosis.PloS one · 2010Article
- [Hereditary head and neck tumors].Der Pathologe · 2010Article
- Purification of FANCD2 sub-complexes.British journal of haematology · 2010Article
- Formaldehyde and leukemia: epidemiology, potential mechanisms, and implications for risk assessment.Environmental and molecular mutagenesis · 2010Review
- A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.BMC medical genetics · 2010Article
- Emerging roles of deubiquitinases in cancer-associated pathways.IUBMB life · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fanconi anemia (FA) is a rare genetic disorder characterized by aplastic anemia, cancer/leukemia susceptibility and cellular hypersensitivity to DNA crosslinking agents, such as cisplatin. To date, 12 FA gene products have been identified, which cooperate in a common DNA damage-activated signaling pathway regulating DNA repair (the FA pathway). Eight FA proteins form a nuclear complex harboring E3 ubiquitin ligase activity (the FA core complex) that, in response to DNA damage, mediates the monoubiquitylation of the FA protein FANCD2. Monoubiquitylated FANCD2 colocalizes in nuclear foci with proteins involved in DNA repair, including BRCA1, FANCD1/BRCA2, FANCN/PALB2 and RAD51. All these factors are required for cellular resistance to DNA crosslinking agents. The inactivation of the FA pathway has also been observed in a wide variety of human cancers and is implicated in the sensitivity of cancer cells to DNA crosslinking agents. Drugs that inhibit the FA pathway may be useful chemosensitizers in the treatment of cancer. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.